Your session is about to expire
← Back to Search
Repetitive Transcranial Magnetic Stimulation
rTMS for Bipolar Disorder
N/A
Waitlist Available
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Summary
This trial is testing whether a special type of brain stimulation called high dose spaced theta-burst rTMS can help reduce depression in people with bipolar disorder who haven't responded to other treatments. The study will also look for markers in the brain that can predict who will benefit from this treatment. Theta-burst stimulation (TBS) is a newer form of repetitive transcranial magnetic stimulation (rTMS) that has shown similar or greater effects on brain activity compared to standard rTMS.
Who is the study for?
This trial is for adults aged 18-70 with bipolar depression who haven't improved after at least two different treatments. Participants must score at least 20 on the MADRS depression scale, meet DSM 5 criteria for Bipolar I or II, be able to consent, and pass a safety screen for TMS. They should be on stable medication including one mood stabilizer.
What is being tested?
The study tests if high dose spaced theta-burst rTMS can significantly reduce depressive symptoms in bipolar disorder compared to sham treatment over five days. It also aims to identify biomarkers in the brain that could predict remission from bipolar depression after treatment.
What are the potential side effects?
While not explicitly stated here, common side effects of rTMS may include headache, scalp discomfort during stimulation, lightheadedness, and rare risk of seizure; however individual experiences may vary.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Assessment of Biomarkers
Change in Hamilton Rating Scale for Depression (HRSD-17) Scores
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Scores
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active iTBSExperimental Treatment1 Intervention
Patients will receive unilateral accelerated theta-burst stimulation to the left dorsal lateral prefrontal cortex for 5 consecutive days, with a total of 10 hours a day. Treatment will be 10min with 50min of breaks in between the 10 sessions.
Group II: Sham iTBSPlacebo Group1 Intervention
Patients will receive sham unilateral accelerated theta-burst stimulation to the left dorsal lateral prefrontal cortex for 5 consecutive days, with a total of 10 hours a day. Treatment will be 10min with 50min of breaks in between the 10 sessions.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Repetitive transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT) are neuromodulation techniques used to treat Bipolar Disorder by targeting specific brain regions to alter neural activity. rTMS uses magnetic fields to stimulate nerve cells in the brain, particularly in the prefrontal cortex, which is associated with mood regulation. ECT involves inducing controlled seizures through electrical currents, which can lead to significant mood improvements.
These treatments are particularly relevant for patients who do not respond to traditional pharmacotherapy, such as lithium or antipsychotics, which work by stabilizing mood through neurotransmitter regulation. Understanding these mechanisms helps patients and clinicians make informed decisions about treatment options, especially when conventional medications are ineffective.
Find a Location
Who is running the clinical trial?
University of California, San DiegoLead Sponsor
1,180 Previous Clinical Trials
1,574,996 Total Patients Enrolled
13 Trials studying Bipolar Disorder
1,921 Patients Enrolled for Bipolar Disorder
Milken InstituteOTHER
7 Previous Clinical Trials
214 Total Patients Enrolled
6 Trials studying Bipolar Disorder
208 Patients Enrolled for Bipolar Disorder
University of PennsylvaniaOTHER
2,076 Previous Clinical Trials
42,719,765 Total Patients Enrolled
5 Trials studying Bipolar Disorder
667 Patients Enrolled for Bipolar Disorder
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not have a severe illness like widespread cancer or kidney failure.I have depression that hasn't improved after trying at least two different antidepressants.I have been diagnosed with bipolar depression.I am on a consistent medication plan that includes at least one mood stabilizer.My depression is severe, scoring 20 or more on a scale.I do not have depression as my main health issue.I don't have implants or conditions that make TMS or MRI unsafe for me.My gender does not affect my eligibility.I have been diagnosed with bipolar depression.I have depression that hasn't improved after trying at least 2 different antidepressants.I am between 18 and 70 years old.I am on a consistent medication plan that includes at least one mood stabilizer.
Research Study Groups:
This trial has the following groups:- Group 1: Sham iTBS
- Group 2: Active iTBS
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger